<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">Cerebral vasospasm</z:e> leading to delayed <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> is a common and serious complication of aneurysmal <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> that often results in increased morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Treatments for <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>, including triple-H therapy (therapeutic <z:hpo ids='HP_0011105'>hypervolemia</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and hemodilution), nimodipine, balloon angioplasty, and intra-arterial <z:chebi fb="1" ids="35620">vasodilators</z:chebi> have limitations in their efficacy and safety profiles </plain></SENT>
<SENT sid="2" pm="."><plain>Nicardipine, a <z:chebi fb="1" ids="38215">calcium channel blocker</z:chebi>, is available for intravenous administration for blood pressure reduction </plain></SENT>
<SENT sid="3" pm="."><plain>A recent study reported its efficacy in the treatment of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> when given intrathecally (IT) </plain></SENT>
<SENT sid="4" pm="."><plain>We present our experiences with IT nicardipine for treatment of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: IT nicardipine was administered to six patients with aneurysmal <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> after prophylactic and aggressive therapeutic management for vasospasm failed </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In these patients, IT nicardipine treatment was followed within 8 hours by a 43.1 +/- 31.0 cm/s decrease in middle cerebral arterial flow velocity, as measured by transcranial Doppler ultrasound </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Based on these positive results, we believe that larger scale studies evaluating the safety and efficacy of IT nicardipine for the management of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> are warranted </plain></SENT>
</text></document>